Ausgabe 2/2019
Inhalt (12 Artikel)
The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
Jens U. Marquardt, Anna Saborowski, Carolin Czauderna, Arndt Vogel
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Fabienne Lucas, Jennifer A. Woyach
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
Qianqian Guo, Xiaojie Lin, Lingling Ye, Rui Xu, Yan Dai, Yuzhu Zhang, Qianjun Chen
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
Toshio Takagi, Hironori Fukuda, Tsunenori Kondo, Hiroki Ishihara, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
Xiang Chen, JiaXi Yao, Li Liu, WenZhong Zheng, XiaoYi Hu, YanJun Zhu, Hang Wang, JianMing Guo
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
Anna Buder, Ulrike Setinek, Maximilian J. Hochmair, Sophia Schwab, Klaus Kirchbacher, Andrea Keck, Otto C. Burghuber, Robert Pirker, Martin Filipits
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Nicolò Bendinelli, Emanuele Forcesi, Marco Tuccori, Ugo Moretti, Elisabetta Poluzzi, Fabrizio De Ponti
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
Pei San Yee, Nur Syafinaz Zainal, Chai Phei Gan, Bernard K. B. Lee, Kein Seong Mun, Mannil Thomas Abraham, Siti Mazlipah Ismail, Zainal Ariff Abdul Rahman, Vyomesh Patel, Sok Ching Cheong